

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	)
	)
<b>LESKOVAR</b>	) Group Art Unit: Unassigned
	)
Serial No. Unassigned	)
	) Examiner: Unassigned
Filed: Concurrently	)
	)
For: "DRUGS AND METHODS FOR	)
TREATING CANCER"	)

1c971 U.S. PTO  
10/087252  
03/01/02

INFORMATION DISCLOSURE STATEMENT

BOX PATENT APPLICATION  
Commissioner for Patents  
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.  
Suite 1200, The Candler Building  
127 Peachtree Street, N.E.  
Atlanta, Georgia 30303-1811

March 1, 2002

Sir:

Submitted herewith is a copy of a form PTO-1449 as originally filed in parent application Serial No. 09/302,642, filed May 3, 1999, with the docket number, serial number and filing date of the parent application struck through and those of the present application written in. Also enclosed is a new form PTO-1449 listing documents cited by the examiner in the parent application on form PTO-892. Each of the references listed on these forms PTO-1449 was previously submitted or cited by the examiner and is of record in the parent application. Thus, copies are not provided.

Consideration of the cited documents and making the same of record in the prosecution of the above-noted application are respectfully requested.


Applicants believe that this Information Disclosure Statement is being filed in accordance with 37 C.F.R. § 1.97(b)(1) and (3), i.e., within three months of the filing date of the application or before the mailing date of the first Office Action on the merits. Therefore, no fee is believed to be due.

**ATTORNEY DOCKET NO. 07038.0003U2**  
**SERIAL NO.: Unassigned**

However, the Commissioner is hereby authorized to charge any fees which may be required, or to credit any overpayment, to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE &amp; ROSENBERG, P.C.

  
Gwendolyn D. Spratt  
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.  
Suite 1200, The Candler Building  
127 Peachtree Street, N.E.  
Atlanta, Georgia 30303-1811  
404/688-0770

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as U.S. Express Mail Envelope No. E1924205666US in an envelope addressed to: Box Patent Application, Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

  
David Thorpe

3-1-02  
Date

07038.000362

ATTORNEY DOCKET NO. 07038-0003

SERIAL NO. 097302,642

Page 1 of 1

Unassigned

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE  LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.: 07038.0003 <i>V2</i>	SERIAL NO. <i>Unassigned</i> <del>097302,642</del>
	APPLICANT: Leskovar et al.	
	FILING DATE: <del>May 3, 1999</del> <i>March 1, 2002</i>	GROUP: <del>4642</del> <i>Unassigned</i>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,894,227	1/16/90	Stevens et al.	424	85.2	

## FOREIGN PATENT DOCUMENTS


## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AB	Sigma Biochemical, pages 1119 and 1120, 1991
AC	Naito et al. "Effect of Continuous Administration of Interleukin 2 on Active Specific Chemoimmunotherapy with Extracted Tumor-specific Transplantation Antigen and Cyclophosphamide" <i>Cancer Res.</i> 43:101-108, January 1, 1988
AD	Kim et al. "Immunotherapy of Pulmonary Metastases Using Monoclonal Antibody to T-Cell Suppressor Factor and Interleukin 2", <i>Arch. Surg.</i> 122:1455-1459, December 1987
AE	Simpson, E. & Chandler, P. "Analysis of Cytotoxic T Cell Responses", <i>British J. Haematology</i> , Blackwell Scientific Publications, Vol.67, No. 4, Chapter 68, pp. 68.1 - 68.16, December 1987
AF	Severinson, E. and Larsson, E., "Lymphocyte Responses to Polyclonal B and T Cell Activators", <i>British J. Haematology</i> , Blackwell Scientific Publications, Vol.67, No. 4, Chapter 63, pp. 63.1 - 63.18, December 1987
AG	Titus et al. "Human K/Natural Killer Cells Targeted with Hetero-Cross-Linked Antibodies Specifically Lyse Tumor Cells <i>In Vitro</i> and Prevent Tumor Growth <i>In Vivo</i> " <i>J. Immunol.</i> 139(9):3153-3158, November 1, 1987
AH	Jung et al. "Induction of Cytotoxicity in Human Peripheral Blood Mononuclear Cells by Monoclonal Antibody OKT3" <i>J. Immunol.</i> 139 (2):639-644, July 15, 1987
AI	Sugarbaker et al. "Inhibitory Effects fo Alloimmune T Cells on the Generation of Cytolytic Responses of Lymphokine-Activated Killer Cells" <i>J. Biol. Responses Mod.</i> 6:430-445, 1987

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE	<b>ATTORNEY DOCKET NO.:</b> 07038.0003U2	<b>SERIAL NO.</b> Unassigned (Continuation of 09/302,642)
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)		
<b>APPLICANT:</b> Leskovar		<b>FILING DATE:</b> March 1, 2002
		<b>GROUP:</b> Unassigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
A1		Gura et al. Systems for identifying new drugs are often faulty. <i>Science</i> V278:1041-1042 (1997)
A2		Spitler. Cancer vaccines: the interferon analogy. <i>Cancer Biotherapy</i> 10:1-3 (1995)

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.